BMS' Orencia equals Abbott's Humira for patient outcomes
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has reported one-year analyses from the head-to-head AMPLE study, this time showing similar clinical improvements in Patient Reported Outcomes (PROs) with its rheumatoid arthritis (RA) drug, Orencia (abatacept) compared with Abbott's RA product, Humira (adalimumab).